{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:40:56Z","timestamp":1777581656059,"version":"3.51.4"},"reference-count":221,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"AbbVie srl"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Ophthalmology"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:p>The high prevalence of Diabetic macular edema (DME) is a real global health problem. Its complex pathophysiology involves different pathways. Over the last decade, the introduction of intravitreal treatments has dramatically changed the management and prognosis of DME. Among the different treatment options, inhibitors of vascular endothelial growth factor (anti-VEGF) and intravitreal steroids implants represent the first-line therapy of DME. We conducted a review of electronic databases to compile the available evidence about the clinical management of DME in a clinical setting, with a special focus on treatment-na\u00efve patients. Anti-VEGF therapies represent a valuable option for treating DME patients. However, many patients do not respond properly to this treatment and, due to its administration regimen, many patients receive suboptimal treatment in real life. Current evidence demonstrated that in patients with DME, DEX-i improved significantly both anatomic and visual outcomes. Besides eyes with insufficient anti-VEGF respond or recalcitrant DME cases, DEX-i can be effectively and safely used in treatment-na\u00efve DME patients as first line therapy. DEX-i may be considered first line therapy in different clinical scenarios, such as DME eyes with a greater inflammatory component, patients with cardiovascular events, vitrectomized eyes, or those requiring cataract surgery. In conclusion, there are still many points for improvement pending in the clinical management of the patient with DME. Since DME treatment must follow a patient-tailored approach, selecting the best therapeutic approach for each patient requires a good understanding of the pathophysiology of DME.<\/jats:p>","DOI":"10.1177\/11206721241237069","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T03:28:45Z","timestamp":1710127725000},"page":"1675-1694","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Management of treatment-na\u00efve diabetic macular edema patients: Review of real-world clinical data"],"prefix":"10.1177","volume":"34","author":[{"given":"Francesco","family":"Boscia","sequence":"first","affiliation":[{"name":"Department of Translational Medicine and Neurosciences (DiBraiN), University of Bari, Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0148-5348","authenticated-orcid":false,"given":"Daniele","family":"Veritti","sequence":"additional","affiliation":[{"name":"Department of Medicine \u2013 Ophthalmology, University of Udine, Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiana","family":"Iaculli","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Policlinico Riuniti Di Foggia, University of Foggia, 71122, Foggia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosangela","family":"Lattanzio","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Freda","sequence":"additional","affiliation":[{"name":"AbbVie S.r.l., SR 148 Pontina, 04011, Campoverde, LT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"Piergentili","sequence":"additional","affiliation":[{"name":"AbbVie S.r.l., SR 148 Pontina, 04011, Campoverde, LT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6530-1563","authenticated-orcid":false,"given":"Monica","family":"Varano","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, IRCCS \u2013 Fondazione Bietti, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,3,11]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108072"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1159\/000315156"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1159\/000455277"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v2.i6.98"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.86.7.716"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2008.10.001"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2011.05.002"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.03.024"},{"key":"e_1_3_3_11_2","first-page":"2156273","article-title":"Diabetic macular edema pathophysiology: vasogenic versus inflammatory","author":"Romero-Aroca P","year":"2016","unstructured":"Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, et al. Diabetic macular edema pathophysiology: vasogenic versus inflammatory. J Diabetes Res 2016; 2016: 2156273. doi:https:\/\/doi.org\/10.1155\/2016\/2156273","journal-title":"J Diabetes Res"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/2045-3701-4-27"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2016.08.022"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2017.10.006"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.07-0112"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/191382"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-015-4853-0"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2010.362"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1159\/000458539"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/08820538.2016.1228388"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-019-1188-4"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2019.107417"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0b013e318219c171"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.946"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb1609216"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15102461"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.10.019"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S236423"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_1240_18"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.iae.0000247165.38655.bf"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.12.028"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.03.016"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.02.048"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318176de48"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001790"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-022-02006-5"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-021-01509-x"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11082125"},{"key":"e_1_3_3_39_2","first-page":"37","article-title":"Assessment of anti-VEGFs in treating diabetic macular edema in Alfaisal eye center, Khartoum, Sudan, 2019","volume":"14","author":"Ahmedalgabri RHM","year":"2022","unstructured":"Ahmedalgabri RHM, Omer T, Zarroug F, et al. Assessment of anti-VEGFs in treating diabetic macular edema in Alfaisal eye center, Khartoum, Sudan, 2019. Clin Pharmacol. 2022; 14: 37\u201347.","journal-title":"Clin Pharmacol."},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-021-00416-4"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.iae.0000242842.14624.e7"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0548-1"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6654168"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-307249"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-018-0513-2"},{"issue":"3","key":"e_1_3_3_46_2","first-page":"200","article-title":"Visual outcomes following intravitreal ranibizumab for diabetic macular edema in a pro Re nata protocol from baseline: a real-world experience","volume":"8","author":"James DGP","year":"2019","unstructured":"James DGP, Mitkute D, Porter G, et al. Visual outcomes following intravitreal ranibizumab for diabetic macular edema in a pro Re nata protocol from baseline: a real-world experience. Asia Pac J Ophthalmol (Phila) 2019; 8(3): 200\u2013205.","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.11.018"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-020-01510-0"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S281501"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1159\/000497406"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1159\/000511591"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.05.038"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S131381"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10633-017-9601-2"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47241-1"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2015.209"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1159\/000453006"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2018.03.009"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13520"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006459"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14145"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-018-0970-7"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-017-0554-8"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8825082"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2017.111"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2016-309313"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-20855"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2016.09.002"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-016-3562-0"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00347-019-01004-5"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1177\/1120672120930603"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000003428"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1159\/000505070"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0421-y"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S62778"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S154421"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-019-04592-9"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-019-00224-x"},{"issue":"2","key":"e_1_3_3_79_2","first-page":"47","article-title":"Functional and anatomic results of up to 24 months aflibercept treatment for diabetic macular edema in real-life setting","volume":"22","author":"Tsapardoni FN","year":"2019","unstructured":"Tsapardoni FN, Makri OE, Lagogiannis AP, et al. Functional and anatomic results of up to 24 months aflibercept treatment for diabetic macular edema in real-life setting. Hell J Nucl Med 2019; 22(Suppl 2): 47\u201354.","journal-title":"Hell J Nucl Med"},{"issue":"2","key":"e_1_3_3_80_2","first-page":"64","article-title":"Effect of baseline central retinal thickness on the results of treatment of diabetic macular edema with aflibercept: real-life evidence in the Czech Republic","volume":"78","author":"N\u011bm\u010dansk\u00fd J","year":"2022","unstructured":"N\u011bm\u010dansk\u00fd J, Stepanov A, Veith M, et al. Effect of baseline central retinal thickness on the results of treatment of diabetic macular edema with aflibercept: real-life evidence in the Czech Republic. Cesk Slov Oftalmol 2022; 78(2): 64\u201370.","journal-title":"Cesk Slov Oftalmol"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.1177\/1120672119833270"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1177\/1120672120927275"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1177\/1120672120925034"},{"key":"e_1_3_3_84_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S304030"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S352152"},{"key":"e_1_3_3_86_2","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14946"},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCMA.0000000000000680"},{"key":"e_1_3_3_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2019.03.012"},{"key":"e_1_3_3_89_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-021-01625-8"},{"key":"e_1_3_3_90_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S338478"},{"key":"e_1_3_3_91_2","doi-asserted-by":"publisher","DOI":"10.4103\/tjo.tjo_85_20"},{"key":"e_1_3_3_92_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-83811-y"},{"key":"e_1_3_3_93_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246626"},{"key":"e_1_3_3_94_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_459_20"},{"key":"e_1_3_3_95_2","doi-asserted-by":"publisher","DOI":"10.1177\/0300060520985369"},{"key":"e_1_3_3_96_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78954-3"},{"key":"e_1_3_3_97_2","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.9.11.2"},{"key":"e_1_3_3_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.05.006"},{"key":"e_1_3_3_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.06.017"},{"key":"e_1_3_3_100_2","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13945"},{"key":"e_1_3_3_101_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.12.030"},{"key":"e_1_3_3_102_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.03.057"},{"key":"e_1_3_3_103_2","first-page":"3025","article-title":"Preclinical pharmacology and safety of ESBA1008, a single-chain antibody fragment, investigated as potential treatment for age related macular degeneration","volume":"53","author":"Gaudreault J","year":"2012","unstructured":"Gaudreault J, Gunde T, Floyd HS, et al. Preclinical pharmacology and safety of ESBA1008, a single-chain antibody fragment, investigated as potential treatment for age related macular degeneration. Invest Ophthalmol Vis Sci. 2012; 53: 3025. Available in: https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2354604 Last accessed November 29, 2022.","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"e_1_3_3_104_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.12.031"},{"key":"e_1_3_3_105_2","doi-asserted-by":"publisher","DOI":"10.1055\/a-1101-9126"},{"key":"e_1_3_3_106_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2022.01.004"},{"key":"e_1_3_3_107_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000849"},{"key":"e_1_3_3_108_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.11.011"},{"key":"e_1_3_3_109_2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2028772"},{"key":"e_1_3_3_110_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells9081869"},{"key":"e_1_3_3_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00018-6"},{"key":"e_1_3_3_112_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414264"},{"key":"e_1_3_3_113_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.02.022"},{"key":"e_1_3_3_114_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2016.09.012"},{"key":"e_1_3_3_115_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-020-01496-7"},{"issue":"15","key":"e_1_3_3_116_2","first-page":"5047","article-title":"Editorial - suboptimal response to intravitreal anti-VEGF treatment for patients with diabetic macular edema: is there any point in switching treatment?","volume":"22","author":"Chatziralli I","year":"2018","unstructured":"Chatziralli I. Editorial - suboptimal response to intravitreal anti-VEGF treatment for patients with diabetic macular edema: is there any point in switching treatment? Eur Rev Med Pharmacol Sci. 2018; 22(15): 5047\u20135050.","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"e_1_3_3_117_2","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20170829-10"},{"key":"e_1_3_3_118_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2022.04.001"},{"key":"e_1_3_3_119_2","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v4.i6.295"},{"key":"e_1_3_3_120_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.03.033"},{"key":"e_1_3_3_121_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.122.12.1801"},{"key":"e_1_3_3_122_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(97)01464-7"},{"key":"e_1_3_3_123_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(01)01010-8"},{"key":"e_1_3_3_124_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318188c6e2"},{"key":"e_1_3_3_125_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e31818144a7"},{"issue":"9","key":"e_1_3_3_126_2","article-title":"A randomized trial comparing intravitreal triamcinolone acetonide and focal\/grid photocoagulation for diabetic macular edema","volume":"115","author":"Diabetic Retinopathy Clinical Research Network","year":"2008","unstructured":"Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal\/grid photocoagulation for diabetic macular edema. Ophthalmology 2008; 115(9): 1447\u20139, 1449.e1\u201310.","journal-title":"Ophthalmology"},{"issue":"4","key":"e_1_3_3_127_2","first-page":"317","article-title":"Sustained release intraocular drug delivery devices for treatment of uveitis","volume":"6","author":"Haghjou N","year":"2011","unstructured":"Haghjou N, Soheilian M, Abdekhodaie MJ. Sustained release intraocular drug delivery devices for treatment of uveitis. J Ophthalmic Vis Res 2011; 6(4): 317\u2013329.","journal-title":"J Ophthalmic Vis Res"},{"key":"e_1_3_3_128_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-5285"},{"key":"e_1_3_3_129_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.04.024"},{"key":"e_1_3_3_130_2","doi-asserted-by":"publisher","DOI":"10.1159\/000356413"},{"key":"e_1_3_3_131_2","doi-asserted-by":"publisher","DOI":"10.1159\/000371770"},{"key":"e_1_3_3_132_2","doi-asserted-by":"publisher","DOI":"10.1159\/000381356"},{"key":"e_1_3_3_133_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2015.246"},{"key":"e_1_3_3_134_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001234"},{"key":"e_1_3_3_135_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-017-0332-x"},{"issue":"1","key":"e_1_3_3_136_2","first-page":"77","article-title":"Intravitreal dexamethasone implants for diabetic macular edema","volume":"11","author":"Pareja-R\u00edos A","year":"2018","unstructured":"Pareja-R\u00edos A, Ruiz-de la Fuente-Rodr\u00edguez P, Bonaque-Gonz\u00e1lez S, et al. Intravitreal dexamethasone implants for diabetic macular edema. Int J Ophthalmol 2018; 11(1): 77\u201382.","journal-title":"Int J Ophthalmol"},{"key":"e_1_3_3_137_2","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13935"},{"key":"e_1_3_3_138_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002196"},{"key":"e_1_3_3_139_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-018-1151-x"},{"key":"e_1_3_3_140_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-018-1022-9"},{"key":"e_1_3_3_141_2","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/4860743"},{"key":"e_1_3_3_142_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.10.005"},{"key":"e_1_3_3_143_2","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2021.10.15"},{"key":"e_1_3_3_144_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-020-01716-2"},{"key":"e_1_3_3_145_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2021-319070"},{"issue":"1","key":"e_1_3_3_146_2","first-page":"43","article-title":"The efficacy of single-dose intravitreal dexamethasone implant for diabetic macular edema refractory to anti-VEGF therapy: real-life results","volume":"5","author":"Simsek M","year":"2020","unstructured":"Simsek M, Citirik M, Ozates S, et al. The efficacy of single-dose intravitreal dexamethasone implant for diabetic macular edema refractory to anti-VEGF therapy: real-life results. Beyoglu Eye J 2020; 5(1): 43\u201348.","journal-title":"Beyoglu Eye J"},{"key":"e_1_3_3_147_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S303670"},{"key":"e_1_3_3_148_2","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8882539"},{"key":"e_1_3_3_149_2","doi-asserted-by":"publisher","DOI":"10.11604\/pamj.2021.39.108.23528"},{"key":"e_1_3_3_150_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-07604-7"},{"key":"e_1_3_3_151_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S345947"},{"key":"e_1_3_3_152_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-021-00395-6"},{"key":"e_1_3_3_153_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10225342"},{"key":"e_1_3_3_154_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S336865"},{"key":"e_1_3_3_155_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.649979"},{"key":"e_1_3_3_156_2","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8840689"},{"key":"e_1_3_3_157_2","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6639418"},{"key":"e_1_3_3_158_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-79288-w"},{"key":"e_1_3_3_159_2","doi-asserted-by":"publisher","DOI":"10.1177\/1120672120949761"},{"key":"e_1_3_3_160_2","doi-asserted-by":"publisher","DOI":"10.1177\/11206721221076697"},{"key":"e_1_3_3_161_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-23042"},{"key":"e_1_3_3_162_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-018-0779-1"},{"key":"e_1_3_3_163_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S206769"},{"key":"e_1_3_3_164_2","doi-asserted-by":"publisher","DOI":"10.1177\/1120672119857511"},{"issue":"5","key":"e_1_3_3_165_2","first-page":"601","article-title":"Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. JAMA ophthalmol. 2018;136(3):257\u2013269","volume":"136","author":"Bressler NM","year":"2018","unstructured":"Bressler NM, Beaulieu WT, Glassman AR, et al.; Diabetic Retinopathy Clinical Research Network. Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. JAMA ophthalmol. 2018;136(3):257\u2013269. Erratum in: JAMA Ophthalmol 2018; 136(5): 601.","journal-title":"Erratum in: JAMA Ophthalmol"},{"key":"e_1_3_3_166_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2017-310242"},{"key":"e_1_3_3_167_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-019-00865-7"},{"key":"e_1_3_3_168_2","doi-asserted-by":"publisher","DOI":"10.1177\/1120672119848257"},{"key":"e_1_3_3_169_2","doi-asserted-by":"publisher","DOI":"10.1177\/1120672120929960"},{"key":"e_1_3_3_170_2","first-page":"1053","article-title":"Early switch to the dexamethasone implant after sub-optimal response to anti-VEGF therapy for diabetic macular edema","volume":"62","author":"Kavoussi S","year":"2021","unstructured":"Kavoussi S, Nezgoda J, Chhablani JK, et al. Early switch to the dexamethasone implant after sub-optimal response to anti-VEGF therapy for diabetic macular edema. IOVS 2021; 62: 1053. Available in: https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2774927 Last accessed July 4, 2022.","journal-title":"IOVS"},{"issue":"11","key":"e_1_3_3_171_2","first-page":"3569","article-title":"Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device","volume":"41","author":"Jaffe GJ","year":"2000","unstructured":"Jaffe GJ, Yang CH, Guo H, et al. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci 2000; 41(11): 3569\u20133575.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_3_172_2","unstructured":"Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg for intravitreal injection data sheet. Available in https:\/\/webcache.googleusercontent.com\/search?q=cache:gu3-KoUuX6gJ:https:\/\/www.alimerasciences.com\/wp-content\/uploads\/2016\/02\/Prescribing-Information.pdf(&cd=1&hl=es&ct=clnk&gl=es Last accessed July 4 2022."},{"key":"e_1_3_3_173_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.11.024"},{"key":"e_1_3_3_174_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2016.301"},{"key":"e_1_3_3_175_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2017.125"},{"key":"e_1_3_3_176_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-018-0726-1"},{"key":"e_1_3_3_177_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-018-0155-5"},{"key":"e_1_3_3_178_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-019-0197-3"},{"key":"e_1_3_3_179_2","doi-asserted-by":"publisher","DOI":"10.1177\/1120672119834474"},{"key":"e_1_3_3_180_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2018-312284"},{"key":"e_1_3_3_181_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-315984"},{"key":"e_1_3_3_182_2","doi-asserted-by":"publisher","DOI":"10.1177\/1120672119898414"},{"key":"e_1_3_3_183_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S283561"},{"key":"e_1_3_3_184_2","first-page":"1012","article-title":"Extended real-world experience with the ILUVIEN\u00ae (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the medisoft\u00ae audit study","author":"Bailey C","unstructured":"Bailey C, Chakravarthy U, Lotery A, et al. Medisoft Audit Group. Extended real-world experience with the ILUVIEN\u00ae (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the medisoft\u00ae audit study. Eye (Lond) 2022; 36(5): 1012\u20131018.","journal-title":"Eye (Lond)"},{"key":"e_1_3_3_185_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13010072"},{"key":"e_1_3_3_186_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14040723"},{"key":"e_1_3_3_187_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2022.01.015"},{"key":"e_1_3_3_188_2","doi-asserted-by":"publisher","DOI":"10.1177\/1120672120982948"},{"key":"e_1_3_3_189_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-84362-y"},{"key":"e_1_3_3_190_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.12.028"},{"key":"e_1_3_3_191_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.04.030"},{"key":"e_1_3_3_192_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2017.06.026"},{"key":"e_1_3_3_193_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0420.2005.00387.x"},{"key":"e_1_3_3_194_2","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/491835"},{"key":"e_1_3_3_195_2","doi-asserted-by":"publisher","DOI":"10.1177\/1120672120939500"},{"key":"e_1_3_3_196_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-002-0530-7"},{"key":"e_1_3_3_197_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2005.087403"},{"key":"e_1_3_3_198_2","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/126984"},{"key":"e_1_3_3_199_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.08.002"},{"key":"e_1_3_3_200_2","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4896036"},{"key":"e_1_3_3_201_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01506-8"},{"key":"e_1_3_3_202_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-62561-3"},{"key":"e_1_3_3_203_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-020-01509-5"},{"key":"e_1_3_3_204_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002974"},{"key":"e_1_3_3_205_2","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14516"},{"key":"e_1_3_3_206_2","doi-asserted-by":"publisher","DOI":"10.1177\/11206721211062037"},{"key":"e_1_3_3_207_2","doi-asserted-by":"publisher","DOI":"10.1177\/1120672118781236"},{"key":"e_1_3_3_208_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-007-0660-z"},{"key":"e_1_3_3_209_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.05.062"},{"key":"e_1_3_3_210_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.03.045"},{"key":"e_1_3_3_211_2","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2012.393"},{"key":"e_1_3_3_212_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.04.026"},{"key":"e_1_3_3_213_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2013.242"},{"key":"e_1_3_3_214_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.14-14188"},{"key":"e_1_3_3_215_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3182278ab4"},{"key":"e_1_3_3_216_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318217ffde"},{"key":"e_1_3_3_217_2","doi-asserted-by":"publisher","DOI":"10.3109\/08820538.2013.835833"},{"key":"e_1_3_3_218_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.02.034"},{"key":"e_1_3_3_219_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-019-01453-z"},{"key":"e_1_3_3_220_2","doi-asserted-by":"publisher","DOI":"10.1177\/1120672119861623"},{"key":"e_1_3_3_221_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S320948"},{"key":"e_1_3_3_222_2","doi-asserted-by":"publisher","DOI":"10.15537\/smj.2021.2.25623"}],"container-title":["European Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11206721241237069","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11206721241237069","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11206721241237069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:46:13Z","timestamp":1777405573000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11206721241237069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,11]]},"references-count":221,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1177\/11206721241237069"],"URL":"https:\/\/doi.org\/10.1177\/11206721241237069","relation":{},"ISSN":["1120-6721","1724-6016"],"issn-type":[{"value":"1120-6721","type":"print"},{"value":"1724-6016","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,11]]}}}